Memorandum on the Medicare
Laboratory Date of Service Rule
Executive
summary
This memorandum was written by Chat GPT in its “deep research” mode,
after I gave it brief remarks on some of the key dates to look for (1997, 2001,
2006.)
I would add an explanation of how outpatient hospital patients have been handled:
Outpatient Hospital Specimens
1) Before 2006, tests from hospital outpatients to outside labs were
generally billed by the outside lab to its local MAC.
2) The 2006 rule abruptly changed this, requiring billing by the
hospital only. This raised the risk its
local MAC might not cover, or might inappropriately price, the test run by the
distant lab when billed by the local hospital.
3) In 2013, CMS made most routine lab tests bundled to hospital
outpatient events (like surgery or E.R.)
However, CMS stated that
molecular pathology tests were payable – if they were billed only by the local
hospital to its local MAC and on the patient's biopsy DOS.
4) In 2017, CMS stated that molecular pathology tests could be billed
by whichever lab performed them, and, on the date they were performed. Hospital labs would bill CMS using their
local date of test performance, and outside reference labs would bill CMS using
their date of test performance, and billing the lab’s own MAC.
The rest of this memo is written by Chat GPT in “deep research” mode.
The operative congressional push for national laboratory uniformity, requested
by industry, came from the 1997 Balanced Budget Act, enacted by the U.S.
Congress[1]. The required negotiated-rulemaking process began in 1998, produced a
proposed rule in March 2000, and culminated in a November 23, 2001 final rule
by the CMS. That 2001 rule, not the 2006 rule, is where
CMS first selected specimen collection as the default national date
of service for laboratory claims. CMS implemented the policy in 2002
program memoranda, clarified the archived-specimen concept in 2005, and
codified the modern DOS framework in 42 CFR 414.510 in December 2006, effective
January 1, 2007. Strictly speaking, the “14-day rule” is only one branch of the
broader Date of Service policy, not the whole policy. [2]
The strongest modern reform case is not that CMS acted irrationally in 2006. It is that the rule was built for a late-1990s uniformity and anti-unbundling problem, while today’s oncology market relies far more heavily on post-discharge molecular decision support. In 2006 CMS focused on relatively narrow stored-specimen and chemo-sensitivity scenarios and repeatedly emphasized fear of unbundling hospital care. In 2017 CMS itself acknowledged that the existing DOS policy could delay outpatient molecular testing, then created a direct-billing outpatient exception for qualifying molecular pathology tests and Criterion A ADLTs, while expressly declining to extend the same logic to inpatient specimens because of DRG/IPPS ratesetting implications. That means any serious stakeholder effort to change inpatient policy must combine the clinical-access argument with a narrow test list, anti-gaming safeguards, and a credible answer on inpatient payment policy. [3]
Origins in fragmentation and negotiated rulemaking
The legal origin is section 4554 of the Balanced Budget Act of 1997.
That section required the Secretary to adopt national coverage and
administrative policies for clinical diagnostic laboratory tests under Part B
by January 1, 1999, using negotiated rulemaking. The same section also created
a regional-carrier framework for lab claims, reflecting Congress’s view that
laboratory administration had become too fragmented and should be made more
uniform. The statute expressly tied the project to program integrity, national
uniformity, and simpler administration. [4]
When the agency published its June 3, 1998 notice of intent to form the
negotiated-rulemaking committee, it described the task in those exact terms.
The notice said the committee would negotiate national coverage and
administrative policies designed to promote program integrity and national
uniformity, and it identified likely priority tests as those subject to wide
divergence among local Medicare carriers, high-volume tests, or tests whose
clinical utility was controversial. The committee’s meetings began in July
1998, and CMS later reported that the committee met through January 1999 and
reconvened in August 1999 to discuss comments on the draft proposed rule. [5]
The negotiated-rule project was broader than DOS. The March 10, 2000
proposed rule and the November 23, 2001 final rule addressed claim information,
documentation, coding, recordkeeping, frequency limits, and test-specific
coverage policy. The final rule also incorporated 23 laboratory NCDs. DOS was
therefore one administrative policy among many, but it became unusually
consequential because the date of service is a required claim field and
determines whether a test falls inside or outside bundled hospital payment. [6]
How DOS was defined before codification
In the 2001 final rule, CMS explained that laboratory claims can
involve several different dates: the order date, specimen-collection date,
accession date, test date, and result date. CMS chose specimen collection as
the national default because DOS is a required data field, because all
laboratories needed to report it consistently, and because CMS believed the
collection date most closely tracks when the test was ordered. CMS presented
that choice as a national-uniformity and program-integrity measure. The agency
also noted that earlier instructions, including a 1995 program memorandum for
certain automated multichannel hospital tests, had not produced a single,
stable national approach. [7]
That same 2001 rule already recognized the stored-specimen problem. CMS
said that for laboratory tests using specimens from stored collections, DOS
should be the date the specimen was obtained from the archives. So the policy
did not simply insist that a clearly archived paraffin block must always
inherit the original biopsy date. The unresolved issue after 2001 was
definitional: how long a specimen had to be stored before it qualified as
“archived.” [7]
CMS then operationalized the new DOS rule in a September 27, 2002
program memorandum. That memorandum instructed contractors that DOS should be
reported as the specimen-collection date, required the person obtaining the
specimen to furnish the collection date to the billing entity, and allowed up
to a 12-month grace period for systems changes. In February 2005 CMS resolved
the main archival ambiguity by defining an archived specimen as one stored for
more than 30 calendar days before testing. Specimens stored 30 days or less
retained the collection date as DOS, and CMS also clarified that multiday
collections should use the date the collection ended. [8]
The 2006 and 2008 architecture that created the modern rule
The modern regulatory structure arrived in the December 1, 2006
physician fee schedule final rule, which created 42 CFR 414.510 effective
January 1, 2007. The regulation established a general rule that DOS is the
specimen-collection date and then set out several exceptions. For stored
specimens, if the specimen had been stored more than 30 days, DOS became the
date the specimen was obtained from storage. If the specimen had been stored 30
days or less, DOS could instead become the date the test was performed only if
five conditions were met: the physician ordered the test at least 14 days after
hospital discharge; the specimen had been collected during a hospital surgical
procedure; it would have been medically inappropriate to collect the sample
elsewhere; the result did not guide treatment during the hospital stay; and the
test was reasonable and medically necessary. CMS also created a similar
date-of-performance exception for chemotherapy-sensitivity testing on live
tissue. [9]
That point is important because the familiar “14-day rule” was not
originally a blanket rule for every post-discharge laboratory test. It was a
narrow date-of-performance exception nested inside a broader DOS framework for
particular stored-specimen and live-tissue scenarios. CMS said it was
responding to concerns about tests related to cancer recurrence and therapeutic
interventions, but it simultaneously refused to create a shorter-than-14-day
exception. CMS’s explanation was direct: tests ordered less than 14 days after
discharge were harder to distinguish from the hospital care itself, and the
agency was “very concerned” about unbundling services that should remain
associated with the hospital stay. That anti-unbundling rationale remains the
core policy logic behind the rule. [10]
CMS then broadened the scope in the November 27, 2007 physician fee
schedule final rule by applying § 414.510 not only to clinical laboratory
services but also to the technical component of physician pathology services.
CMS said the collection-date logic was similar for both and that using one DOS
framework would improve claims processing, payment accuracy, and
duplicate-detection efforts. CMS later updated claims-processing instructions
in 2008. So, from that point forward, the DOS policy applied to clinical
laboratory testing and to the technical component of anatomic-pathology-type
physician pathology services, not only to chemistry-style laboratory testing. [11]
The outpatient molecular carve-out and the current regulation
CMS reopened the DOS issue in the 2017 OPPS/ASC rulemaking because the
older DOS framework collided with newer hospital-outpatient molecular testing.
In the final rule published December 14, 2017, CMS said commenters had reported
administrative complexity and delayed ordering for molecular pathology tests
and certain ADLTs. CMS also recognized that these tests were already separately
paid under the Clinical Laboratory Fee Schedule rather than packaged under OPPS
and that they generally guide care after discharge, not treatment during the
same outpatient encounter. On that basis, CMS created a new exception under §
414.510(b)(5), effective January 1, 2018, allowing the performing laboratory to
bill Medicare directly for qualifying outpatient molecular pathology tests and
Criterion A ADLTs when the test is performed after outpatient discharge and the
other criteria are met. [12]
The same 2017 final rule also drew the line that still blocks inpatient
reform. CMS stated that the new exception would not apply to specimens
collected from hospital inpatients and said that an inpatient DOS exception
would have “policy and ratesetting implications” under IPPS DRG payment. That
distinction is fundamental. For outpatients, the 2018 revision mainly changed
the billing channel for tests that CMS already regarded as separately payable
outside OPPS. For inpatients, a comparable change would push payment outside
the DRG and therefore raises direct hospital-payment and ratesetting questions.
[13]
The current version of 42 CFR 414.510 reflects later expansions beyond
the 2018 outpatient carve-out. CMS’s current DOS webpage states that the
general rule remains specimen collection unless the physician orders the test
at least 14 days after hospital discharge, and it notes later exceptions for
outpatient molecular pathology tests, Criterion A ADLTs, cancer-related
protein-based MAAAs, and CPT 81490. The current eCFR text confirms that §
414.510(b)(5) now covers those categories, but still only in the hospital
outpatient setting and still only when the result does not guide treatment
during that outpatient encounter. [14]
Why the rule matters more for oncology now
The 2006 rulemaking record reads like a policy aimed at edge cases, not
modern comprehensive genomic profiling. CMS was discussing stored tissue used
after discharge, tests related to cancer recurrence and therapeutic
interventions, and a few comments about high-complexity live-tissue
chemotherapy-sensitivity assays. By 2017, however, CMS was describing molecular
pathology as a relatively new class of tests often performed by only a few
specialized laboratories, and it acknowledged that hospitals might delay
ordering until day 14 or even cancel orders to avoid DOS consequences. That
progression strongly supports the inference that the rule’s operational burden
in contemporary precision oncology is much larger now than it was when the
14-day threshold was adopted. [15]
Professional biomarker guidance shows why those delays matter
clinically. Lung-cancer molecular-testing guidance has recommended that key
results be available within two weeks, or 10 working days, of specimen receipt
in the testing laboratory, with a faster pathway in clinically urgent cases.
Colorectal-cancer molecular-biomarker guidance likewise says results should be
available as promptly as feasible to inform treatment decisions and suggests a
benchmark that 90 percent of reports be available within 10 working days of
receipt in the molecular diagnostics laboratory. Those benchmarks do not prove
that every inpatient oncology case is harmed by the DOS rule, but they do show
that a reimbursement structure that rewards waiting until day 15 sits awkwardly
beside prevailing expectations for timely molecular decision support. [16]
Enforcement history also shows that the rule creates unhealthy
operational incentives. The U.S. Department of Justice[17] alleged that Caris Life Sciences[18] and Genomic Health[19] delayed testing, tolerated or encouraged cancel-and-reorder behavior,
or otherwise manipulated the 14-day boundary to bill Medicare directly. Caris
paid about $2.9 million in 2022, and Genomic Health agreed to pay $32.5 million
in 2023, both without admissions of liability. The uploaded Genomic Health
summary points in the same direction as the official DOJ materials: the
compliance risk is not theoretical. fileciteturn0file1 [20]
A comparison with the three-day payment window sharpens the policy
contrast. CMS explains that the 3-day window stems from OBRA 1990’s expansion
of a longstanding same-day bundling policy and requires hospitals to include
all outpatient diagnostic services, plus admission-related outpatient
nondiagnostic services, furnished in the three days before an inpatient
admission on the inpatient bill. The DOS rule works differently: it is narrower
in service type because it is about laboratory and pathology DOS attribution,
but it is unusual in being forward-looking after discharge. That is why
stakeholders often experience the 14-day rule as uniquely distorting in
oncology even though Medicare has other bundling doctrines. [21]
The strongest reform case and the strongest rebuttals
The strongest reform proposal is a narrow inpatient extension of logic
CMS has already accepted for outpatient advanced oncology testing, not a
wholesale repeal of hospital bundling. The ask should be to allow DOS to be the
date the test is performed for a tightly defined set of post-discharge cancer
assays on inpatient surgical specimens when the result does not guide inpatient
treatment. The natural starting categories are the ones CMS already recognizes
in the outpatient setting: molecular pathology tests, Criterion A ADLTs, and
perhaps the later cancer-related protein-based MAAA categories. That framing
keeps the proposal anchored in existing CMS doctrine rather than asking the
agency to invent a wholly new payment philosophy. [22]
The best affirmative argument is clinical coherence. CMS has already
said that certain outpatient molecular tests are distinguishable from hospital
care because they guide posthospital management and are not tied to the primary
outpatient encounter. The same logic can apply to inpatient surgical tissue
when the clinically meaningful action happens after discharge, especially in
oncology. Advocates should emphasize that the proposal is not about routine
chemistry, routine microbiology, or tests that would change inpatient
management if available immediately. It is about a narrow class of
post-discharge oncology decision tools. The 2006 regulation already used this
sort of line-drawing by conditioning separate DOS treatment on whether the
result guides hospital-stay treatment, and CMS used the same concept again in
the outpatient molecular exception. [3]
The second strong argument is that the present rule rewards exactly the
wrong behavior. CMS heard in 2017 that hospitals may delay ordering or cancel
orders so laboratories can bill directly after day 14, and DOJ later brought
enforcement actions alleging that this kind of manipulation happened in the
market. A better rule would remove the waiting-game incentive by making
eligibility turn on the nature of the specimen, the type of test, and whether
the result guides inpatient care, not on whether the provider deliberately
waited out an arbitrary day-count. That is also the best rebuttal to the
predictable objection that shortening the waiting period would invite gaming:
the current 14-day cliff already creates the gaming incentive. [23]
The third strong argument is timing. Modern oncology biomarker practice
norms aim for results within roughly 10 working days of specimen receipt, not
after a reimbursement-triggered lull. That does not mean every inpatient
specimen must be carved out of the DRG, but it does mean that a rule crafted
for an earlier laboratory market now sits awkwardly beside present-day
treatment sequencing. Stakeholders should make that argument with code-level
data: how many affected tests are ordered on inpatient surgical tissue, how
often hospitals cannot perform them in-house, the median added delay
attributable to the current billing rule, and whether treatment planning or
trial enrollment is postponed. CMS has already shown that it is responsive to
operational evidence when it sees a distinct pattern of post-discharge clinical
use. [24]
The strongest pushback will be fiscal and structural, not conceptual.
CMS has already said that an inpatient exception has IPPS/DRG ratesetting
implications. Opponents will argue that moving tests outside the DRG increases
Part B spending, fragments a bundled hospital payment, and could allow
hospitals and laboratories to shift costs out of inpatient payment. The most
credible rebuttal is not denial. It is to concede that inpatient reform is
different from outpatient reform and to pair the policy request with a narrow
code list, explicit “does not guide inpatient treatment” criteria,
data-reporting modifiers, and a proposed mechanism for CMS to study or adjust
rates prospectively if needed. In other words, stakeholders should show that
they understand the budget-model problem and have a manageable answer for it. [25]
The second major pushback will be program integrity. CMS was worried
about unbundling in 2006, and DOJ’s later settlements give that concern real
force. The rebuttal here should be to build guardrails into the reform request
itself: preserve False Claims Act and Anti-Kickback enforcement; prohibit
cancel-and-reorder workarounds; require retention of the original order date
and specimen-collection date; require attestation that results did not guide
inpatient treatment; and make the exception unavailable when the hospital
laboratory itself performs the assay as part of its own inpatient service. A
reform proposal that ignores these issues will fail; a proposal that absorbs
them into the design has a better chance. [26]
If stakeholders want a fallback position for the inpatient setting, the
most defensible secondary ask is a short post-discharge period for specified
oncology assays rather than the current 14-day waiting period. A three-day
concept is not current CMS policy, but it has two argumentative advantages: it
is materially less distortionary than 14 days, and it creates rough symmetry
with Medicare’s broader preadmission bundling logic, even though the 3-day
payment window is not a doctrinally identical rule. If CMS resists eliminating
the time gate altogether, advocates can present a 3-day rule as a compromise
that limits strategic delay while still preserving a brief separation between
inpatient treatment and post-discharge molecular management. [27]
The most persuasive overall message to CMS is therefore narrow and
practical: the agency should not unbundle ordinary inpatient lab care, but it
should update a late-1990s uniformity rule so that a defined set of modern
post-discharge oncology assays are paid according to the clinical role CMS
already recognizes in the outpatient setting. That argument is strongest when
it is framed not as a laboratory revenue request, but as a targeted removal of
an incentive to delay medically important cancer testing. [25]
[1] [12] [13] [17] [18] [22] [23] [24] [25]
https://www.federalregister.gov/documents/2017/12/14/R1-2017-23932/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment
[2] [4]
https://www.govinfo.gov/link/plaw/105/public/33
https://www.govinfo.gov/link/plaw/105/public/33
[3] [10] [15] [26]
https://www.govinfo.gov/content/pkg/FR-2006-12-01/pdf/FR-2006-12-01.pdf
https://www.govinfo.gov/content/pkg/FR-2006-12-01/pdf/FR-2006-12-01.pdf
[5] https://www.govinfo.gov/content/pkg/FR-1998-06-03/pdf/98-14798.pdf
https://www.govinfo.gov/content/pkg/FR-1998-06-03/pdf/98-14798.pdf
[6] https://www.govinfo.gov/content/pkg/FR-2000-03-10/pdf/00-4834.pdf
https://www.govinfo.gov/content/pkg/FR-2000-03-10/pdf/00-4834.pdf
[7] https://www.govinfo.gov/content/pkg/FR-2001-11-23/pdf/01-29027.pdf
https://www.govinfo.gov/content/pkg/FR-2001-11-23/pdf/01-29027.pdf
[8]
https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/ab02129.pdf
https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/ab02129.pdf
[9]
https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.510
https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.510
[11] https://www.govinfo.gov/content/pkg/FR-2007-11-27/pdf/07-5506.pdf
https://www.govinfo.gov/content/pkg/FR-2007-11-27/pdf/07-5506.pdf
[14]
https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/date-service-policy
[16] [19]
https://documents.cap.org/documents/2013-cap-lung-cancer-egfr-alk-tki-guideline.pdf
https://documents.cap.org/documents/2013-cap-lung-cancer-egfr-alk-tki-guideline.pdf
[20]
https://www.justice.gov/usao-edny/pr/caris-life-sciences-pays-over-28-million-settle-false-claims-act-allegations-delay
[21] [27]
https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/downloads/jsmtdl-10382-attachment.pdf
